Solitary plasmacytoma of jaw bone: A case report and systematic review of fifty cases from literature

Harshal Suryavanshi1, Sangeeta Patankar2, Snehal Dhumal2, Sheetal Choudhari2
Departments of 1Oral and Maxillofacial Surgery and 2Oral and Maxillofacial Pathology and Microbiology, YMT Dental College and Hospital, Kharghar, Navi Mumbai, Maharashtra, India

Abstract
Solitary plasmacytoma of bone (SPB) is a localized form of plasma cell neoplasm where jaw involvement is rare. Distinguishing SPB from other plasma cell neoplasms is critical for treatment and survival. Here, a case of SPB of mandible in an elderly female is reported. Histopathological diagnosis of plasma cell neoplasm was confirmed immunohistochemically with MUM1 and CD138 positivity and multiple myeloma (MM) was ruled out on performing systemic workup. Prognosis of SPB worsens when it transforms into MM. A systematic review was undertaken with the objective to determine the factors affecting conversion of SPB to MM. An electronic search was undertaken with PubMed/MEDLINE, Web of Science and Science Direct. Fifty cases of SPB of jaw from 29 publications were reviewed. SPB commonly presents as a painless swelling. Radiographically, it is commonly seen as multilocular radiolucency with well-defined borders. Follow-up data showed that nine cases turned into MM in a mean duration of 1 year 9 months and 12 patients died after median disease-free survival of 6 years 9 months. Prognosis of SPB is found to be affected by tumor size (≥5 cm), anaplasia of tumor cells, Ki-67 labeling index, vascularity of the tumor, presence of clonal bone marrow plasma cells, serum immune globulin level, dose of radiotherapy and persistence of M protein after treatment. There is a need to identify prognostic subgroups in SPB based on these factors. Furthermore, studies are necessary for standardization of treatment protocol to halt or prolong the progression of SPB to MM.

Keywords: Multiple myeloma, plasma cell neoplasm, plasmacytoma of jaw bone, plasmacytoma, solitary plasmacytoma of mandible, solitary plasmacytoma, treatment of plasmacytoma

INTRODUCTION
Plasma cell neoplasms are relatively unusual malignancies of the head-and-neck region. The incidence of these tumors is about 2.6–3.3/100,000 populations. These neoplasms are characterized by monoclonal neoplastic proliferation of plasma cells and are indistinguishable histologically. They may present as multiple myeloma (MM), solitary plasmacytoma of bone (SPB), or extramedullary plasmacytoma (EMP). Behavior of each of these tumors is variable with the difference in prognosis. SPB and EMP are the localized forms of plasma cell neoplasms, while MM is a disseminated form. The prognosis of SPB is poorer than EMP and MM is the most fatal among them.
SPB is localized plasmacytoma and is rare in the orofacial region. Only 4.4% of SPB have been reported in mandible mainly in angulus and ramus area. Prognosis of SPB worsens when it transforms into MM. Careful differentiation between SPB and MM is necessary. Distinguishing SPB from other plasma cell neoplasms is critical for treatment and survival. Here, we are reporting a case of SPB of mandible in an elderly female.

**CASE REPORT**

An elderly, partially edentulous female patient (of age 56 years) reported with a complaint of swelling in the left posterior region of mandible. Swelling gradually increased over a period of 4 months. Clinically, the swelling was of 5 cm × 3 cm in size and was extending from 33 to 36 with buccal vestibular obliteration, covered with normal intact mucosa. On palpation, swelling was found to be slightly tender and firm in consistency. There was no evidence of mobility with involved teeth. On extraoral examination, paraesthesia of the lower lip was noticed. On panoramic radiography, a well-corticated unilocular radiolucency extending from 33 to 36 was seen. Root resorption of 35 and 36 was also noticed [Figure 1]. Three-dimensional cone-beam computed tomography (CT) scan revealed diffuse to slightly clear radiolucency and loss of buccal and lingual cortical plates [Figure 2]. These features were indicative of an aggressive benign odontogenic tumor. An incisional biopsy was taken [Figure 3], and specimen was sent for histopathological examination.

Microscopically [Figure 4], it exhibited diffuse sheets of intensely basophilic cells infiltrating into surrounding connective tissue. The cells presented vesicular nuclei, prominent nucleoli and perinuclear halo. These histopathological features were indicative of plasma cell neoplasm. To confirm the diagnosis, panel of immunohistochemical markers was used which showed positive expression for CD138, MIB1 and MUM1 [Figures 5-7]. CD138 and MUM1 were suggestive of terminally differentiated plasma cells. MIB1 labeling index was about 25%–30% in the present case. The lesion was found to be negative for CD20, CD3, leukocyte common antigen (LCA), Mic-2 and synaptophysin. On performing systemic workup such as blood examination, radiographic survey and magnetic resonance imaging (MRI) of spine and pelvis, MM was ruled out. On the basis of these findings, final diagnosis of solitary plasma cell neoplasm of mandible was given. The patient was then referred to the oncology department for further treatment and is disease free for 1 year.

A systematic review was undertaken to integrate the available data on SPB of jaw to determine the factors which may affect the conversion of SPB to MM and to explore the therapeutic considerations which can prevent its conversion to MM. An electronic search was undertaken in August 2019. The search strategy was in agreement with the Cochrane guidelines for systematic reviews. PubMed/MEDLINE, Web of Science and Science Direct were searched using the keywords as SPB; solitary plasmacytoma of jaw OR mandible OR maxilla; and treatment for...
plasmacytoma. Case reports and reviews on SPB of jaw published from 2000 to August 2019 were searched. Inclusion criteria comprised cases of SPB of jaw bone with sufficient clinical, radiographical, histological and treatment details. Exclusion criteria composed of publications of MM, EMP and recurrent MM presenting as SPB.

Fifty cases of SPB from 29 publications which had sufficient clinical, radiological, histopathological and treatment details were included. Twenty-six cases of SPB were found to be reported in mandible and 24 in maxilla. The mean age of occurrence was found to be 55.8 years. In males, the mean age of occurrence was 48.87 years and in females it was found to be 57.94 years. Male-to-female ratio was 1.07:1. The most common clinical appearance was of a painless swelling (46%). Pain was reported in 31.37% of cases, ulceration/red lesions in 3.9% of cases, mobility of involved teeth in 5.8% of cases and paraesthesia and pathological fracture in 5.8% cases. Presentation of nasal obstruction has been reported in 14.28% of cases of SPB of maxilla. Radiographically, SPB of jaw is commonly seen as multilocular radiolucency (47.7%) with well-defined borders (80.9%). While unilocular radiolucency is reported in 22.4% of cases with well-defined borders in 10.2% and ill-defined borders in 12.2% of cases. In 19.8% of cases, radio-opacity was noted mostly in lesions involving maxilla. SPB is diagnosed on histopathological examination which needs to be supported by immunohistochemistry to establish the confirmative diagnosis after ruling out MM.

According to this review of jaw SPB cases, 18 (36.73%) cases were treated by radiotherapy (RT) alone, 13 (26.5%) cases were treated by RT in combination with surgery, 6 (12.24%) cases by surgery alone, 4 (8.16%) cases by RT with chemotherapy (CHT), whereas 3 (6.12%) cases were treated by combination of surgery, RT and CHT and one case was treated by combination of surgery and CHT. In six case reports, treatment details are not available. Eleven cases which were treated by surgery followed by RT had no
It manifests as single swelling. In head-and-neck region, SPB is very rare with an incidence of 12%–15% and 4.4% in mandible. In SPB of jaw bone, chronic irritation or preceding trauma can also act as trigger for plasma cell proliferation and infiltration.

In the present case, patient’s chief complaint was painless swelling in the left posterior region of mandible. As per the review, the most common clinical presentation of SPB was found to be painless swelling [Table 1]. Lombardo et al., in their review reported painless increase in volume as the most common clinical finding in SPB of jaw. Pisano et al. in their study of 13 cases of SPB reported ulceration and hemorrhage as primary symptom along with pain and swelling. In the present review, male-to-female ratio was found to be 1.08:1 and mean average age of occurrence was found to be 55.8 years.

Radiographically, SPB presents as a well-defined, unilocular or multilocular destructive lesion. Lae et al., in their study on 21 SPB cases, reported unilocular radiolucency with cystic appearance as the common radiographic presentation of SPB. Moulopoulos et al., reported that most of their patients with SPB had lytic destructive lesion on conventional radiograph. SPB clinically and radiographically mimics an odontogenic tumor which makes the diagnosis even more difficult. Kanazawa et al. have categorized the variable radiological features of SPB into three categories as multilocular radiolucent area resembling ameloblastoma or myxoma, unilocular radiolucent area with an odontogenic cyst such as appearance and third, i.e., irregular destructive bone resorption suggestive of malignant bone tumor. Therefore, SPB could be misdiagnosed on radiological features as odontogenic tumor or cyst. According to 2017 IMWG guidelines, positron emission tomography/CT (PET/CT) scan is mandatory for diagnosis of SPB. CT is helpful to detect the extent of bone destruction accurately. According to IMWG, the updated criteria for the diagnosis of SPB are single area of bone destruction due to clonal plasma cells, absence of M-protein in serum and/or urine, bone marrow not consistent with MM (plasma cells <10%), normal skeletal survey (and MRI of spine and pelvis if done) and no related organ or tissue impairment.

A definitive diagnosis of SPB based solely on the hematoxylin and eosin light microscopic findings is difficult because of the frequent absence of distinguishing features. Ancillary techniques such as immunohistochemical, ultra-structural, cytogenetic and molecular techniques may be used to aid in the confirmative diagnosis of SPB. Homogenous infiltration of plasma cells can be proved on histopathology and on immunohistochemistry where cells show unequivocal positivity for CD138 and/or CD38. Monoclonal proliferation of plasma cells can be confirmed by the presence of kappa/lambda light chain restriction or by polymerase chain reaction-based approach. Histopathologically, it is necessary to differentiate SPB from plasmablastic lymphoma (PBL). Features such as neoplastic cells exhibiting abundant cytoplasm, vesicular chromatin and central nuclei with prominent nucleoli are commonly observed in PBL. Neoplastic cells of PBL are positive for CD38, MUM1, CD138 and VS38c, while CD20 is not expressed in PBL. In our case, immunohistochemical analysis showed CD138, MIB1, MUM1 and Ki67 positivity, while the tumor was negative for CD20, CD3, LCA, Mic-2 and synaptophysin which ruled out lymphoma, leukemia, Ewing’s sarcoma and neuroendocrine metastasis. CD138
Table 1: Review of 50 cases of solitary plasmacytoma of jaw with clinical and radiographic features, immunohistochemical findings, treatment and follow-up details

| Author, year        | Age/sex | Site             | Clinical features                                                                 | Radiographic features                                                                 | Immunohistochemistry                                                                 | Treatment                                                                 | Follow-up details                                                                 |
|---------------------|---------|------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Matsumura et al., 2000[5] | 83/male | Right maxilla    | Swelling of buccal gingiva and pain on percussion of involved teeth               | IOPA-multilocular honeycomb appearance OPG-radiopaque lesion                        | Positive staining for IgG and λ light chain                                       | 60 Gy RT delivered in 20 fractions by 4-mV x-rays combined with CHT-intravenous cyclophosphamide 100 mL and prednisolone (15 mg×3 per day) 3 times a week given during RT | Follow-up for 6 months and decrease in size of lesion                           |
| Muzio et al., 2001[6] | 53/male | Right mandible   | Pain and paraesthesia                                                             | OPG-bone resorption with vacuolar images CAT-osteolytic area with erosion of buccal and lingual cortical plates | Monoclonal restriction for lambda chain                                           | Refused to surgery. RT of 4000 rads over 20 day's period. CHT for 12 months-Cyclophosphamide 100 mg, prednisolone 100 mg; scaling down prednisolone-m 25 mg after 5th day with melphalan orally 10 mg daily every 4 weeks for 12 months | 6 years follow-up with no recurrence                                             |
| Lae et al., 2002[7], 21 cases | 14 cases-males, 7 cases-females Mean age - 57.7 years | 15 cases-maxilla, 6 cases-mandible | 17 cases-swelling, 5 cases-infected teeth, 5 cases-nasal obstruction, 2 cases-headache, 1 case-pathologic fracture | Multilocular soap-bubble appearance, unilocular radiolucency with cystic appearance, and ill-defined, destructive bony lesion | Details not available                                                             | 8 cases- RT, 8 cases- surgery+RT, 3 cases-surgery+RT+CHT, 1 case-surgery+CHT, 1 case-surgery                                                                                         | 9 cases progressed to MM in median of 20.7 months 12 patients died after median disease-free survival of 6.75 years |
| Yoon et al., 2003[8] | 15/male | Right mandible   | Severe gingival enlargement, size-3 cm×2 cm                                       | Displaced second molar, PDL widening                                               | Positivity for kappa chain and IgG. *In situ* hybridization with EBV encoded RNA- positive signals in tumour cells | RT 4000 rads daily for 3 weeks                                                   | 7 years follow-up with no recurrence                                              |
| Anil, 2006[9]       | 52/male | Right maxilla    | Pain and swelling, size-4.5 cm×2.5 cm                                             | Diffuse radiolucency apical to 15, 16. Parasal sinus view-radiopacity filling sinus | Details not available                                                             | Details not available                                                              | Follow-up for 5 years with no recurrence                                          |
| Canger et al., 2006[10] | 76/female | Anterior mandible | Slowly developed indurated and nontender swelling of size 5.5 cm                  | OPG-multilocular radiolucent lesion of size-6 cm×3.5 cm with ill-defined borders     | Details not available                                                             | Details not available                                                              | Deceased before finishing the treatment                                           |
| Poggio, 2007[11]   | 75/female | Left mandible    | History of SPB spine 12 years back. Presented as swelling and pain in chin Nontender, ulcerated swelling following extraction of 16, covered with slough | Panoramic radiograph showed a large transparency                                    | Details not available                                                             | RT                                                                               | Details not available                                                              |
| Rao K et al., 2011[12] | 31/male | Right maxillarytuberosity | Radioluency with slight bony erosion                                              | Positivity for κ light chain                                                          | Details not available                                                             | Details not available                                                              | Details not available                                                              |
| Author, year | Age/sex | Site | Clinical features | Radiographic features | Immunohistochemistry findings | Treatment | Follow-up details |
|-------------|---------|------|-------------------|-----------------------|-------------------------------|-----------|------------------|
| Rodríguez-Caballero et al., 2011 | 64/male | Left preauricular region in maxilla | Painless swelling of size 5 cm, bulging on the mandibular angle | Ill-defined, multilocular, radiolucency, MRI-6.5 cm×5 cm×6.7 cm | CD 138 positivity with kappa light chain restriction | Local RT of 45 Gy | 1 year follow-up with no recurrence |
| Sekar et al., 2011 | 60/female | Both cases- left mandible | Painless swelling of size 5 cm, bulging on the mandibular angle | Case 1-OPG- lytic lesion without sclerotic border, pathologic fracture and impacted 38 present | In both the cases positivity for light chain kappa and negativity for lambda was found | Both cases underwent RT | No recurrence, follow-up duration not mentioned |
| Meziane et al., 2012 | 42/male | Right maxillary sinus | Headache and permanent right nasal obstruction | CT scan-radiopacity in right maxillary sinus and nasal cavity | CD38 positivity and expression of the lambda restricted light chain | Surgery followed by RT | 1 year follow-up with no recurrence |
| Singh et al., 2012 | 38/female | Left posterior mandible | Gradually increased nontender, bony hard swelling of size 2.5 cm×2 cm×2 cm, deviation of chin towards left | OPG-solitary, ovoid, unilocular radiolucent lesion extending along the entire angle- ramus region without sclerotic borders | Details not available | Surgery | No recurrence. Follow-up years not mentioned |
| Ashraf et al., 2013 | 48/male | Left mandible | Pain and numb chin syndrome | CBCT-large destructive lesion of left mandible involving body of mandible and condylar processes | Positivity for kappa light chain and CD38 and MyoD1, desmin, SMA, LCA and cytokeratin negative | Local RT with no significant improvement, later underwent surgery | 9 months follow-up with no recurrence |
| Baad et al., 2013 | 56/male | Posterior mandible | Loose and mobile teeth, pain and swelling of size 6 cm×5 cm | Punched out radiolucency with ill-defined borders | Positivity for Kappa light chain, CD138, CD117 and EMA | Local RT | Details not available |
| Kaur et al., 2013 | 60/male | Left mandible | Swelling with buccolingual cortical plate expansion | OPG- ill-defined, multilocular radiolucent lesion in body of mandible | Positivity for kappa light chain, CD117, and EMA and negative for λ light chain, pan-cytokeratin, vimentin, S-100, CD1a, tryptase, and SMA | Left hemimandib-ullectomy with bone plating | 6 months with no recurrence |
| Obimakinde et al., 2014 | 70/female | Right zygoma | Painless right zygomatic swelling of size 8 cm×10 cm | Plain radiograph-an area of patchy opacity with diffuse opacification of upper half of right maxillary sinus | Lambda light chain positivity | Surgery (modified Al-Kayat access incision) followed by RT | 6 monthly follow-up for 2 years with laboratory analyses of urine and blood. No recurrence reported |
| Author, year | Age/sex | Site | Clinical features | Radiographic features | Immunohistochemistry findings | Treatment | Follow-up details |
|-------------|---------|------|------------------|----------------------|-------------------------------|-----------|------------------|
| Kamal et al., 2014[21] | 60/male | Right mandible | Pedunculated growth of size 3 cm×4 cm present since 3-4 months, associated with dull pain and mobility of teeth | Generalized bone loss | CD138 positivity | Details not available | Details not available |
| Sharma et al., 2015[22] | 54/female | Left mandible | Swelling of size 3 cm×2 cm associated with pain, bluish discoloration of the overlying mucosa | CT-expansion along with loss of trabeculae and slight perforation of the lingual cortical plate | Positive for CD45, EMA, and CD138, negative for CD20 | Surgery+RT | Patient lost for follow-up due to post radiation complications |
| Alrashedi et al., 2015[23] | 60/male | Left posterior mandible | Asymptomatic | OPG-well-defined unilocular radiolucency of size 3 cm×2 cm | Details not available | Recommended RT with dose of at least 40 Gy in 4 weeks | Recommended follow-up at 6-week intervals for 2 years. Details not available |
| Dayisoylu et al., 2015[24] | 70/male | Right mandibular premolar region | Mobility, pain and numbness | Poorly defined destructive radiolucent lesion with expansion of bony cortices | CD138 positivity and monoclonal restriction for Kappa chain | Surgery | Follow-up for 2 years with no recurrence |
| Rajkumar et al., 2015[25] | 55/female | Right palate | Swelling of size 4 cm×6 cm associated with pain | Paranaval sinuses radiograph-opacity of right maxillary sinus Paranaval sinus CT-heterogeneous mass involving right half of hard palate with destruction of posterolateral wall of right maxilla | Positivity for CD 138 and LCA | Details not available | Details not available |
| Rezaei et al., 2016[26] | 46/male | Posterior mandible | Painless swelling since 2 months | Panoramic radiograph-well-defined, multilocular radiolucent lesion MRI-expansile destructive lesion | CD138, vimentin, Ki-67, EMA-positive; LCA, CK, CD3, CD20, CD1, NSE negative | RT-40 Gy in 20 fractions and CHT-cyclophosphamide, hydroxydaun-orubicin and prednisone | Follow-up for 5 years with no recurrence |
| Beegum et al., 2017[27] | 59/female | Right posterior mandible | Gradually increased painless swelling since 1 year | OPG-multilocular lytic lesion CT-expansile lytic lesion with central sclerosis, cortical discontinuity and scalloping | Lambda light chain and CD138, membrane positivity | RT | 6 monthly follow-up for 1 year with no recurrence |

Contd....
| Author, year | Age/sex | Site | Clinical features | Radiographic features | Immunohistochemistry findings | Treatment | Follow-up details |
|-------------|---------|------|-------------------|-----------------------|-------------------------------|-----------|-------------------|
| Balreddy et al., 2017[28] | 31/male | Right posterior mandible | Gradually increased swelling for 7 years with history of SPB of left mandible | CECT- ill-defined, expansile, osteolytic, sclerotic lesion of size 7.1 cm×4.6 cm×7.2 cm with complete destruction of ascending ramus, partial destruction of body of right side of mandible | Lambda light chain restriction with negative kappa | 40 Gy RT in 20 fractions | Follow-up for 3 years with no recurrence |
| Dos Santosa et al., 2018[29] | 57/male | Anterior mandible | Pain and spontaneous drainage of purulent secretion | Unilocular radiolucent lesion with loss of cortical bone plate and resorption involving inferior anterior teeth | Surgery | 6 monthly follow-up for 2 years with no recurrence |
| Ibikunle et al., 2018[30] | 60/female | Right posterior mandible | Toothache of 2 weeks duration. Postextraction hemorrhage on extraction | Periapical radiograph-periradicular radiolucency in association with 47 PA skull view-unilocular radiolucency involving right mandibular angle-ramus region with poorly defined borders | Negative for keratin and CD45 | RT | Details not available |
| Chittemsett-i et al., 2019[31] | 46/female | Right mandible | Pain and swelling of size 5 cm×6 cm | OPG-ill-defined radiolucency | Strong positivity for CD138 and MUM1, variable membrane positivity for CD45 and negativity for CD20. Elevated serum free lambda light chains | Details not available | Details not available |
| Basavaiah et al., 2019, [32], 2 cases | Case 1-58/ female, Case 2-60/ female | Case 1-Hard palate, Case 2-Right zygomatic arch | Not available | Not available | Details not available | Details not available | Details not available |

IOPA: Intra oral periapical, RT: Radiotherapy, CHT: Chemotherapy, CAT: Computed Tomography, OPG: Ortho Pantomogram, MM: Multiple myeloma, PDL: Periodontal ligament, EBV: Epstein-Barr virus, SPB: Solitary plasmacytoma of bone, MRI: Magnetic resonance imaging, CT: Computed tomography, CBCT: Cone-beam computed tomography systems, LCA: Leukocyte common antigen, SMA: Smooth muscle actin, EMA: Epithelial membrane antigen, CK: Cytokeratin, NSE: Neuron-specific enolase, CECT: Contrast-enhanced computed tomography, PA: Posterio-anterio
and MUM1 were suggestive of terminally differentiated plasma cells. In SPB, Ki-67 labeling index is usually reported as 10%.[9] In our case, it was 20%–25%, which suggested high tumor aggressiveness. According to the Durie and Salmon staging system,[43] SPB can be regarded as Stage I MM. Stage I MM is where hemoglobin is >10 g/dL, serum calcium level is normal, bone structure is normal or there is solitary plasmacytoma only and M-component is low (IgG <5 g/dL and IgA <3 g/dL) and urine light chains are <4 g/24 h.[43]

SPB requires a meticulous overview of the patient by the specialist to rule out MM, a fact that would mark a dramatic change in the treatment and prognosis of the patient. To diagnose SPB, there should be absence of clonal plasma cells or presence of <10% clonal plasma cells on a random marrow sample, no other lesions on bone survey, absence of M-protein in both serum and urine and no evidence of systemic myeloma (bone pain, anemia, hypercalcemia, thrombocytopenia, neuropenia and renal failure).[9] MRI, PET/CT can help to determine bone marrow disease.[44] 18F-fluorodeoxyglucose PET (FDG PET) can aid in diagnosing relapse or progression to MM in clinically suspicious SPB cases. Upon positivity on 18F-FDG PET or on presence of bone marrow disease, patients having been suspected of SPB should be upstaged for MM.[44,45]

The treatment modalities available for SPB are RT, surgery and CHT. For SPB of other bones, authors have advised combination therapies such as surgery followed by RT, RT followed by surgery or RT followed by CHT. According to our review of jaw cases, 17 (34.69%) cases were treated by RT alone, 13 (26.5%) cases by RT in combination with surgery, surgery alone in 6 (12.24%) cases, RT with CHT in 4 (8.16%) cases, 3 (6.12%) cases were treated with combination of surgery, RT and CHT and one (2.04%) case was treated with combination of surgery and CHT. In four case reports, authors have not mentioned treatment details but have suggested RT as an ideal treatment modality for SPB. According to our review, RT followed by surgery or surgery followed by RT has been reported as the most common treatment modality. Surgery has been suggested as the treatment of choice in those jaw cases where tumors can be removed with minimal cosmetic or functional deficit or to prevent or stabilize a pathologic mandibular fracture and for rapidly progressive neurological symptoms.[46] However, it has been found that treatment outcome with surgery alone can carry high rates of local recurrence.[47] Jawad et al. found that there is no advantage of surgery alone or RT combined with surgery over RT alone in treatment of SPB of jaw bone.[48] SBP is a highly radiosensitive disease. It has been found that there is an excellent local control rate (>80%) achieved with RT alone.[49] Li et al. have considered RT alone as a more effective treatment modality for SPB over surgery.[50] Majority of data in literature has suggested that higher dose is required during the intend-curate treatment, especially for the bulky or large SPB (of size >5 cm). Lee et al.[7] in his case series of 21 SPB cases reported that seven patients who had surgery followed by adjuvant RT had better survival. As per present review, 11 cases which have been treated by surgery followed by RT had no recurrence. However, to confirm the same, follow-up of longer duration is required. Matsumura et al.[9] had found decrease in tumor size in 6 months when SPB was treated with RT of dose 60 Gy combined with CHT (intravenous cyclophosphamide and prednisolone). Radical RT comprising 40–50 Gy has shown 80% of local disease control in SPB.[7] Some authors have suggested using doses of 40–50 Gy for lesions smaller than 5 cm and >50 Gy for lesions >5 cm. Radiation dose of 45–50 Gy within 4.5–5 weeks, if tolerable by normal tissue, is recommended in clinical practice for SPB. As per the present review of SPB of jaw bone, eight cases which were treated with RT of 40 Gy did not show recurrence or progression into MM. RT should be advised after gross excision of the lesion to eradicate microscopic residual disease in SBP of jaw. A dose-response relationship needs to be established for SBP of jaw bone.

Management of SBP of jaw bone with CHT is questionable. For patients with tumors larger than 5 cm and high-grade histology, adjuvant CHT may be considered. Melphalan and prednisone-based CHT has been reported to give favorable effects. CHT delays the progression time of plasmacytoma to MM. However, its use does not decrease the conversion rate.[51] Authors have suggested that CHT can be kept as a reserved treatment option in cases which progress to MM.[52] Application of CHT to prevent or halt the progression of SPB to MM needs further evaluation. Vascular endothelial growth factor (VEGF) level and increased vascularity are correlated with clinical outcome in SPB. Grade of angiogenesis has been found to be directly associated with the plasma-cell labeling index and inversely with patient survival.[51] According to Kumar et al.,[52] increased angiogenesis may help to detect the possibility of progression of SPB to MM. Therefore, targeting angiogenic compounds such as VEGF or proteasome inhibitors may represent a promising new therapeutic approach to improve prognosis in SPB. Use and quantification of dose of radiation and CHT to prevent conversion of SBP to MM needs to be explored. Clinical trials should focus on the use of adjuvant CHT and/or novel therapeutic agents.
Prognostic factors

Progression to MM, local recurrence and development of new bony lesion other than MM are the three patterns which worsen the prognosis of SPB. Dimopoulos MA et al.\(^{(3)}\) have reported that SPB has a significantly higher risk of progression to MM at a rate of 65%–84% in 10 years and 65%–100% in 15 years. As per our review, out of fifty cases of SPB of jaw bone, 9 cases progressed to MM within 5 years with mean duration of 1 year and 9 months. Eight (89%) of these patients died of the disease after a median survival of 6 years 9 months, while one patient (11%) was alive with the disease 20 years after transformation to MM and 22 years after the diagnosis of SPB. Four patients died due to SPB within a mean duration of 2 years and 4 months, while three patients died of unknown cause in mean duration of 8 years. In 16 cases (32%), there was no recurrence of the disease when followed for 4 months to 7 years with mean duration of follow-up being 2 years 9 months after treatment. In 17 cases (35.9%), recurrence and follow-up data are not available. Once SPB gets converted to MM, the prognosis of the patients with secondary MM is similar to de novo MM patients. Prognosis of SPB to MM is found to be affected by several factors including the tumor size (≥5 cm), presence of bone marrow plasma cells, age of the patient (patients aged 40 years or above), serum immune globulin level (presence of light chains), cervical spondylitis/spine lesions, SPB-related neuropathy, the dose of RT and persistence of M protein after treatment. These factors influence the outcome in SPB patients and may be indicative of progression to MM. Tsang et al.\(^{(14)}\) in their study reported that lesions of size <5 cm resulted in 100% local disease control as compared to SPB cases with tumors >5 cm in size. The presence of M protein in SPB is considered to be an important prognosticator and is helpful in disease monitoring.\(^{(31)}\) Persistence of M-protein detected following RT or a suppression of the normal immunoglobulin classes may indicate poor prognosis in SPB.\(^{(31,35)}\) In our review, one case of SPB which progressed to MM had positive M band. In such cases, adjuvant systemic therapy should be considered. There should be regular checks for the possible presence of M-protein for detecting recurrence or conversion of SPB to myelomatosis. Anaplasia and Ki-67 labeling index can be considered as an important factor deciding the prognosis of SPB. New bone lesions, detected as either generalized osteopenia or new abnormalities on MRI studies, may indicate progression to symptomatic MM. Progression of SPB into MM occurs in two peaks. The first peak is found to occur within 3 years of treatment which can be attributed to undetected existing disease and the second peak is observed after 6–7 years. However, it is difficult to predict which case of SPB will transform to MM. Therefore, after treatment, SPB cases must be closely followed up with routine laboratory monitoring of immunoglobulins and monoclonal proteins in serum using kappa and lambda markers and Bence-Jones proteins in urine for minimum of 5 years. In addition, in case of recurrence or occurrence of new bony lesion, if bone tissue biopsy shows monoclonal plasma cell proliferation, the patient should undergo a repeat bone marrow evaluation to rule out progression to MM.

Future direction for clinical research

Clear guidelines to establish and refine diagnosis as well as treatment modalities in SPB of jaw bone are required. Different imaging techniques should be compared for SPB diagnosis and follow-up. Techniques should be developed to identify prognostic subgroups in SPB. RT or CHT as valid treatment modalities with quantification of their doses to prevent transformation of SPB to MM requires an evaluation. Large prospective clinical trials should be carried out to evaluate addition of systemic treatment (including novel agents) and to define the optimal treatment approach for patients presenting with poor prognostic factors.

CONCLUSION

Plasma cell neoplasms of jaw bones are rare. Distinguishing one from the other has significant implications for treatment and survival. SPB of jaw manifests as a single osteolytic lesion and has better prognosis compared to MM. As found through our review, the most common clinical presentation of SPB of jaw is of a painless swelling, and radiographically, it manifests as multilocular radiolucency with well-defined borders. Diagnosis of the SPB depends on the microscopic evidence of plasma cell proliferation and absence of any other bone involvement. Ancillary techniques such as immunohistochemistry play an important role in distinguishing SPB from other hematological diseases. After treatment, SPB patients must be closely followed up with routine laboratory monitoring of immunoglobulins and monoclonal proteins in serum and Bence-Jones proteins in urine to check the transformation to MM. As SPB can progress to MM, treatment modalities are required to halt or prolong the progression of SPB to MM. Furthermore, there is a need to look for the prognostic factors for SPB of jaw bone-like size of the lesion, anaplasia, vascularity, Ki-67 labeling index and presence or persistence of M band. Large prospective studies to establish the factors which can confirmatively predict the progression of SPB to MM and mechanisms playing role in this transformation are required.
to be explored. Further, RT or CHT as valid treatment modalities with quantification of their doses to prevent transformation of SPB to MM requires an evaluation.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Scoane J, Aguirre-Urizar JM, Esparza-Gómez G, Suárez-Cunqueiro M, Campos-Trapero J, Pomareda M. The spectrum of plasma cell neoplasia in oral pathology. Med Oral 2003;8:269‑80.
2. Cotran R, Kumar V, Robbins S, editors. Robbins Pathologic Basis of Disease. 4th ed. Philadelphia: W.B. Saunders Co; 1989. p. 739‑43.
3. Marotta S, Di Micco P. Solitary plasmacytoma of the jaw. J Blood Med 2011;1:33.
4. Nofsinger YC, Mirza N, Rowan PT, Lanza D, Weinstein G. Head plasmacytoma of the jaw: A case report. Med Oral Patol Oral Cir Bucal 2011;16:e647‑50.
5. Lombardo EM, Maito FL, Heitz C. Solitary plasmacytoma of the jaws: A rare case report. Int J Med and Dent Sci 2013;1:28‑32.
6. Meziane M, Boulaadas M, E starters and M. Solitary plasmacytoma of mandible – Report of 2 cases. Int J Pathol 2011;9:33‑6.
7. Kaewlaad M, Boulaadas M, S. Solitary plasmacytoma of mandible: A rare case report. Int J Med and Dent Sci 2012;1:28‑32.
8. Ashraf MJ, Azarpita N, Khadem B. Anaplastic Solitary plasmacytoma of mandible, masquerading as sarcoma. Pak J Med Sci 2013;29:872‑3.
9. Baad R, Kapse SC, Rathod N, Sonawane K, Thete SG, Naveen MK. Solitary plasmacytoma of the mandible – A rare entity. J Int Oral Health 2013;5:97‑101.
10. Kaur H, Parhar S, Kaura S, Bansal S, Jawanda M, Madhusankari GS, et al. A large painless swelling of the posterior mandible. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:152‑6.
11. Ohimakinde OS, Taiwo OJ, Lawal AO, Adisa AO, Okejo VN, Arotiba JT. Solitary plasmacytoma of the zygoma in a 70-year-old Nigerian: A case report and review of literature. Int J Otolaryngol Head Neck Surg 2014;3:195‑9.
12. Kamal M, Kaur P, Gupta R, Gupta S, Singh S. Mandibular plasmacytoma of jaw – A case report. J Clin Diagn Res 2014;8:2D20‑1.
13. Sharma NK, Singh AK, Pandey A, Verma V. Solitary plasmacytoma of the mandible: A rare case report. Natl J Maxillofac Surg 2015;6:76‑9.
14. Atrashadi KL, Atrashadi SA, Atrashadi MA. A case of missed diagnosis of solitary plasmacytoma mandibular bone involvement: A case report. Int J Basic Appl Sci 2018;7:115‑8.
15. Dayisoylu EH, Cendi O, Cosgunoglu EZ. Solitary plasmacytoma of the mandible: An uncommon entity. Iran Red Crescent Med J 2016;18:e22932.
16. Rajkumar PN, Manjunath NM, Dinesh MG, Pinto PM, Kumar V. Solitary plasmacytoma of maxilla in a HBSAG positive patient: A case report. J Evid Based Med Healthcare 2015;2:8204‑7.
17. Beegum F, Sivasankar S, Nair RG, Shijineed TK, Hasna KK. Unusual presentation of solitary plasmacytoma of mandible with review of literature. IOSR-JDMS 2017;16:67‑72.
18. Balreddy P, Panta P, Reddy S, Gokavarrupa S. Solitary plasmacytoma in mandible with 7 year follow up data. OHDM 2017;16:1‑4.
19. dos Santos KM, Jennifer Gerbera JT, de Almeida Kintopp CC, Kapse SC, Giovani AF. Marginal resection of solitary plasmacytoma in the anterior region of the mandible and dental implant rehabilitation: Report of an unusual case. Ann Med Surg 2018;36:158‑61.
20. Iikunle A, Taiwo A, Brahman R, Abdullahi K, Adewumi M. Solitary plasmacytoma of the mandible: Report of a rare case. Int Biol Biomed J Winter 2018;4:67‑71.
21. Chittemsetti S, Guttikonda VR, Sravya T, Manchikatla PK. Solitary plasmacytoma of mandible: A rare entity. J Oral Maxillofac Pathol 2019;23:136‑9.
22. Basavaiah SH, Lobo FD, Philipose CS, Suresh PK, Sree ram S, Kini H, et al. Clinicopathological spectrum of solitary plasmacytoma: A single centre experience from coastal India. BMC Cancer 2019;19:8011.
23. Kumar S, Paiva B, Anderson KC, Durie B, Langl Gren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328‑46.
24. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1983;1:255‑62.
25. An SY, An CH, Choi KS, Heo MS. Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy. Dentomaxillofac Radiol 2013;42:20110143.
26. Császár J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel. J Hematol Oncol 2018;11:10.
27. Lombardo EM, Maito FL, Heitz C. Solitary plasmacytoma of the jaws: Therapeutic considerations and prognosis based on a case reports systematic survey. Braz J Otorhinolaryngol 2018;84:790‑8.
Suryavanshi, et al.: Solitary plasmacytoma of mandible

38. Pisano JJ, Coupland R, Chen SY, Miller AS. Plasmacytoma of the oral cavity and jaws: A clinicopathologic study of 13 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:265-71.
39. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Lilshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993;11:1311-5.
40. Kanazawa H, Shoji A, Yokoe H, Midorikawa S, Takamiya Y, Sato K. Solitary plasmacytoma of the mandible. Case report and review of the literature. J Craniomaxillofac Surg 1993;21:202-6.
41. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
42. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
43. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 2004;124:717-26.
44. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J 2012;2012:893765.
45. Sharpley FA, Neffa P, Panitsas F, Eyre TA, Kothari J, Subasinghe M, et al. Correction: Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era. PLoS One 2019;14:e0225184.
46. Kim PJ, Hicks RJ, Wirth A. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys 2009;74:740-6.
47. Knobel D, Tsang R, Poortmans P, Belkacemi Y, Bolla M, Oner F, et al. Outcome and patterns of failure in solitary plasmacytoma: A multicenter rare cancer network study. Int J Radiat Oncol Biol Phys 2003;57:S289.
48. Jawad MU, Scully SF. Skeletal plasmacytoma: Progression of disease and impact of local treatment; an analysis of SEER database. J Hematol Oncol 2009;2:41.
49. Ghodke K, Shet T, Epari S, Sengar M, Menon H, Gujral S. A retrospective study of correlation of morphologic patterns, MIB1 proliferation index, and survival analysis in 134 cases of plasmacytoma. Ann Diagn Pathol 2015;19:117-23.
50. Li QW, Niu SQ, Wang HY, Wen G, Li YY, Xia YF, et al. Radiotherapy alone is associated with improved outcomes over surgery in the management of solitary plasmacytoma. Asian Pac J Cancer Prev 2015;16:3741-5.
51. Holland J, Trenkner DA, Wasserman TH, Finchberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer 1992;69:1513-7.
52. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003;101:1715-7.
53. Dimopoulos MA, Hamilos G. Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol 2002;3:255-9.
54. Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, et al. Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 2001;50:113-20.
55. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 2002;94:1532-7.